Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension
In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH.
This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
Not every patient responds the same way to the same treatment, yet healthcare is moving toward a system based on population health. How can researchers, health plans, and providers respond? This month in The American Journal of Managed Care, Jennifer S. Graff, PharmD, and co-authors call for an approach that identifies when differences in patient responses are mostly like to matter, and offering greater flexibility when the patient’s health is most at stake.
Uncompensated care was supposed to be a thing of the past, but it's persisting in many states not expanding Medicaid eligibility. As an alternative, for some high-cost uninsured patients, hospitals are turning to a new option.
Dr. Michael Bell, previously announced as the keynote speaker for the September 25-26 live meeting hosted by The American Journal of Managed Care, this weekend discussed his role in overhauling lab safety at the Centers for Disease Control and Prevention in Atlanta. Attendees at AJMCLive’s Atlanta conference, “Value-Based Decision-Making in Infectious Disease,” will have the chance to hear Dr. Bell discuss the prevention of hospital-acquired infections.